Using machine learning for mortality prediction and risk stratification in atezolizumab‐treated cancer patients: Integrative analysis of eight clinical trials

Yougen Wu,Wenyu Zhu,Jing Wang,Lvwen Liu,Wei Zhang,Yang Wang,Jindong Shi,Ju Xia,Yuting Gu,Qingqing Qian,Yang Hong
DOI: https://doi.org/10.1002/cam4.5060
IF: 4.711
2022-07-27
Cancer Medicine
Abstract:Random forest model with 12 variables could be a useful tool to identify individuals who are most likely to have adverse outcomes (death, disease progression, discontinued study, or discontinued treatment) and clinical benefit from atezolizumab monotherapy. Laboratory tests, and tumor characteristics evaluation performed at baseline before starting immunotherapy may provide an important reference for weighing benefits and risks of therapy. Background Few models exist to predict mortality in cancer patients receiving immunotherapy. Our aim was to build a machine learning‐based risk stratification model for predicting mortality in atezolizumab‐treated cancer patients. Methods Data from 2538 patients in eight atezolizumab‐treated cancer clinical trials across three cancer types (non‐small‐cell lung cancer, bladder transitional cell carcinoma, and renal cell carcinoma) were included. The whole cohort was randomly split into development and validation cohorts in a 7:3 ratio. Machine‐learning algorithms (extreme gradient boosting, random forest, logistic regression with lasso regularization, support vector machine, and K‐nearest neighbor) were applied to develop prediction models. Model performance was mainly assessed by area under the receiver operating characteristic curve (AUC) value, calibration plot, and decision curve analysis. The probability of death risk was then stratified. Results One thousand and three hundred and seventy‐nine (54.33%) patients died. The random forest (RF) model was overall the best in terms of predictive performance, with the AUC of 0.844 (95% confidence interval [CI]: 0.826–0.862) in the development cohort and 0.786 (95% CI: 0.754–0.818) in the validation cohort for predicting mortality. Twelve baseline variables contributing to mortality prediction in the RF model were C‐reactive protein, PD‐L1 level, cancer type, prior liver metastasis, derived neutrophil‐to‐lymphocyte ratio, alkaline phosphatase, albumin, hemoglobin, white blood cell count, number of metastatic sites, pulse rate, and Eastern Cooperative Oncology Group (ECOG) performance status. A total of 1782 (70.2%) patients were separated into the high‐risk and 756 (29.8%) low‐risk groups. Patients in the high‐risk group were significantly more likely to die, experience disease progression, discontinue study, and discontinue treatment than patients in the low‐risk group (all p values 0.05). Conclusion RF model has good performance in mortality prediction and risk stratification for cancer patients receiving atezolizumab monotherapy.
oncology
What problem does this paper attempt to address?